Broadcom: The Market Overreacted To The AI Guidance Optics

AVGO’s post-print reset looks less like a fundamental break and more like an expectations air pocket. When a stock has already discounted a near-perfect AI ramp, the first derivative matters more than absolute beats; that creates a window where even strong execution can underperform if the guide doesn’t re-accelerate the narrative. The second-order effect is that capital is likely rotating within AI semis rather than leaving the theme entirely, favoring suppliers with fresher catalysts and punishing names where ownership is already crowded.

The bigger winner may be the AI infrastructure supply chain, not AVGO alone. If hyperscaler demand is truly stretching into FY2027, the pinch points shift toward advanced packaging, HBM, substrate, and networking bottlenecks, which can force customers to diversify sourcing and accelerate incremental capex across the ecosystem. That dynamic can support peers and equipment vendors even if near-term AVGO multiple expansion is capped.

The contrarian point is that this drawdown may be too large relative to the underlying duration of the AI monetization story. The market is treating a guide miss versus elevated sell-side expectations as evidence of peak growth, but the real signal is that management is still underwriting a multi-year revenue step-up; that typically matters more over 6-12 months than over 1-2 days. The risk is timing: if the next few quarters do not show an inflection in order flow or backlog conversion, the valuation reset can persist longer than momentum buyers expect.

For positioning, the cleanest setup is to use weakness to build exposure rather than chase strength. Near-term, sentiment may stay heavy until the next catalyst proves the AI ramp is not back-end loaded, but that also creates opportunity for options structures where upside participates in a re-rating while downside is defined. If AI spend broadens beyond a handful of hyperscalers, AVGO should regain leadership; if it does not, this remains a stock-specific de-rating even inside a healthy theme.